Merryn Voysey

Merryn Voysey is Professor of Statistics in Vaccinology at the Oxford Vaccine Group. She has extensive experience in leading vaccines research including clinical trials and observational studies, and was the lead methodologist for the Oxford-AstraZeneca vaccine trials. 

Merryn is the Principal Investigator of a global study of measles seroprevalence in infants from 9 countries, and is Chief Investigator of a randomised controlled trial assessing the early administration of measles vaccination in Ugandan infants. With funding from the Bill & Melinda Gates Foundation, she is principal investigator of studies investigating the contribution of T-cell immunity to protection against SARS-CoV-2 infection, correlates of protection and vaccine efficacy for Group B streptococcus vaccines, and a study of pneumococcal vaccine seroefficacy. In addition, she is co-investigator on the EDCTP3 funded PROTECT study: Preparing for Optimal Phase III/IV maternal Group B Streptococcal vaccine trials in Africa.

Merryn serves on the following committees: The UK Commission on Human Medicines Expert Advisory Group on Clinical Trials, Biologicals and Vaccines; the WHO Technical Advisory Group on Group B Streptococcus Vaccine Development; the UK JCVI Subcommittee on GBS Vaccines; and the NIHR Health Technology Assessment Funding Committee. Additionally she chairs the Department of Paediatrics Athena Swan Data subcommittee.

In 2022 Merryn was awarded Australian of the Year in the UK by the Australian High Commission and was a guest of the Australian Government at Westminster Abbey for the Coronation of King Charles III.